Concepedia

Author

Jörg Seraphin

Praxis für Hämatologie und Onkologie

Also Known As

Jörg Seraphin, Jörg Seraphin

17

Publications

959

Citations

6

H-Index

16

Concepts

All Affiliations

Praxis für Hämatologie und OnkologieCharité - Universitätsmedizin BerlinGoethe University FrankfurtTechnical University of MunichEppendorf (Germany)
JS

About

Jörg Seraphin is an author at Praxis für Hämatologie und Onkologie specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

424

2

Health Sciences

1

1

21

3

Cell Biology

1

1

24

4

Gastroenterology

1

1

21

5

Pathology

1

1

24

Jörg Seraphin

×

6

Publications

945

Citations

6

H-Index

YearCitations

Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial

Helmut Oettle, Hanno Riess, Jens Stieler,

Journal of Clinical Oncology

2014

476

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

Uwe Pelzer, Ingo Schwaner, Jens Stieler,

European Journal of Cancer

2011

379

Phase <scp>III</scp> randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (<scp>RADPAC</scp>)

Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk,

International Journal of Cancer

2020

29

Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study

Friederike Braulke, Klaus Jung, Julie Schanz,

Leukemia Research

2013

24

A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).

Salah‐Eddin Al‐Batran, Jorge Riera‐Knorrenschild, Claudia Pauligk,

Journal of Clinical Oncology

2017

21

Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: Results from a large German community-based observational cohort study

Alexander Stein, Volker Petersen, Mathias Schulze,

Acta Oncologica

2014

16

Page 1